The exercise period for warrants TO5 in Dicot starts today

Press release: Uppsala, Sweden, November 1, 2023.  Today, November 1, 2023, the exercise period for warrants of series TO5 in Dicot AB (publ), which were included in the unit issue in January 2023, begins. Subscription period lasts until November 15, 2023. 

Each warrant of series TO5 entitles the holder to subscribe to one new share during the period November 1-15, 2023, to the exercise price of SEK 0.086.

If all warrants are exercised, Dicot will receive approximately SEK 19.4 million before issuing costs. The issue in January with its options TO4 in June and TO5 in November are all primarily aimed at financing the company through a clinical phase 1 study and in parallel preparations for clinical phase 2. After a strong outcome in the issue and TO4, the proceeds from TO5 will primarily be used for preparations and start-up costs for clinical phase 2a.

The last day of trading on Spotlight Stock Market in warrants of series TO5 ("DICOT TO 5") is November 13, 2023. For the warrants not to expire without value, it is required that the holder actively subscribes for shares no later than November 15, 2023, or sells the warrants no later than November 13, 2023. Please note that certain nominees may close their subscriptions earlier than November 15, 2023.

Advisors

Corpura Fondkommission AB (www.corpura.se) act as financial advisor and Advokatfirman Lindahl KB is legal adviser to the Company in connection to the warrants. Hagberg & Aneborn Fondkomission AB acts as issuing agent.

For further information, please contact:

Elin Trampe, CEO                                    Björn Petersson, CFO
Phone: +46 72 502 1010                          Phone: +46 76 109 0000         
E-mail: elin.trampe@dicot.se                     E-mail: bjorn.petersson@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 4,400 shareholders. For more information, please visit www.dicot.se.